Ali Farman, Ahmad Saleem, Abbas Qamar, Qasim Wasim, Saleem Muhammad Zubair, Mohsin Muhammad, Khalid Khurram
Clinical Research Institute, The Second Affiliated Hospital &Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian, 350122, China.
Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Microb Pathog. 2025 Sep;206:107767. doi: 10.1016/j.micpath.2025.107767. Epub 2025 Jun 4.
The global prevalence of Helicobacter pylori (H. pylori) infection has led to the practice of multiple treatments with antibiotics as the standard treatment strategy. However, antibiotic resistance has led to a decline in therapeutic effectiveness, prompting the exploration of innovative and eco-friendly antimicrobial agents. Microbial biosurfactants have gained attention because of their antibacterial activities, making them a good choice for treating various bacterial infections. Therefore, our study aimed to identify active biosurfactants, their potential targets, and the accompanying signaling pathways for the therapy of H. pylori using a network pharmacology approach. We selected twenty biosurfactants from the literature for further investigation. Our analysis identified 119 potential therapeutic targets for H. pylori infection out of the 706 putative targets of biosurfactants and the 913 disease-related targets. GO analysis revealed that these 119 targets were significantly enriched into multiple GO functional categories, such as cell proliferation, and inflammatory response regulation were prominently impacted. Further, through KEGG analysis, signaling pathways, such as the HIF-1 signaling pathway, coronavirus infection, and epithelial cell signaling in H. pylori infection. Protein-protein interaction analysis further revealed 25 core targets as potential targets in the network. Molecular docking was employed to validate the efficacy of biosurfactants against the supposed targets. Remarkably, we observed that biosurfactants like athrofactin, liposan, lichenysin, sophorolipid, and amphisin exhibited strong binding affinities for the proteins EGFR, SRC, MAPK14, JUN, CXCL8, and CASP3, which are participating in the epithelial cell signaling pathway in H. pylori infection. These biosurfactants hold potential as therapeutic targets for treating H. pylori infection. Overall, the integrated approach of network pharmacology and docking analysis has been instrumental in advancing our understanding of biosurfactants potential therapeutic role in combating H. pylori infection.
幽门螺杆菌(H. pylori)感染的全球流行促使人们将使用抗生素进行多种治疗作为标准治疗策略。然而,抗生素耐药性导致治疗效果下降,促使人们探索创新且环保的抗菌剂。微生物生物表面活性剂因其抗菌活性而受到关注,使其成为治疗各种细菌感染的理想选择。因此,我们的研究旨在使用网络药理学方法鉴定活性生物表面活性剂、其潜在靶点以及伴随的信号通路,用于幽门螺杆菌的治疗。我们从文献中选择了20种生物表面活性剂进行进一步研究。我们的分析在生物表面活性剂的706个假定靶点和913个疾病相关靶点中,确定了119个幽门螺杆菌感染的潜在治疗靶点。基因本体(GO)分析表明,这119个靶点显著富集到多个GO功能类别中,如细胞增殖,炎症反应调节受到显著影响。此外,通过京都基因与基因组百科全书(KEGG)分析,发现了一些信号通路,如缺氧诱导因子-1(HIF-1)信号通路、冠状病毒感染以及幽门螺杆菌感染中的上皮细胞信号传导。蛋白质-蛋白质相互作用分析进一步揭示了25个核心靶点作为网络中的潜在靶点。采用分子对接来验证生物表面活性剂对假定靶点的疗效。值得注意的是,我们观察到像节杆菌素、脂聚糖、地衣芽孢杆菌素、槐糖脂和两性霉素等生物表面活性剂对参与幽门螺杆菌感染上皮细胞信号通路的蛋白质表皮生长因子受体(EGFR)、原癌基因酪氨酸蛋白激酶(SRC)、丝裂原活化蛋白激酶14(MAPK14)、原癌基因蛋白(JUN)、趋化因子(CXCL8)和半胱天冬酶3(CASP3)表现出强烈的结合亲和力。这些生物表面活性剂有望成为治疗幽门螺杆菌感染的治疗靶点。总体而言,网络药理学和对接分析的综合方法有助于增进我们对生物表面活性剂在对抗幽门螺杆菌感染中潜在治疗作用的理解。